CD20 is one of the most clinically validated targets for therapeutic antibody development, with approved therapies spanning both oncology and autoimmune disease. While Rituximab, Ofatumumab, and Obinutuzumab have been studied extensively, much of their Fc-mediated biology has been characterized using a relatively limited set of assays. In this webinar, we'll present a comprehensive head-to-head comparison of these three antibodies to explore how evaluating Fc biology in the presence of antigen and across multiple primary human immune cell types can provide a more complete picture of antibody function, helping researchers make more informed decisions during antibody characterization, Fc engineering, and lead selection.

Using a near-native CD20 virus-like particle (VLP) antigen, we'll show how this approach confirms well-established mechanisms of action while uncovering additional Fc-mediated immune pathways involving neutrophils, eosinophils, and dendritic cells. We'll discuss what these findings reveal about antibody biology and how comprehensive Fc profiling can support more informed therapeutic antibody development.

Key Topics:

• Understand the impact of antigen context on antibody function.


• Explore Fc-mediated mechanisms beyond traditional ADCC and CDC.


• Recognize the value of profiling antibodies across multiple primary human immune cell types.


• Evaluate how comprehensive Fc profiling can inform lead selection and Fc engineering.